Chronic myelogenous leukemia also known as CML is a disease in which there is an overproduction of granulocytes and this usually leads to a high white blood cell count. It is induced by the BCR-ABL oncogene. This Gene is a product of the BCR-ABL tyrosine kinase.We’re not able to find a treatment for this disease because first we have to fully understand the biology of LSCs and we also have to identify the significant genes that are able to survive and self-renew in the LSCs. When chronic myelogenous leukemia comes to mind there are many possible drug threats that are the TK inhibitors that are a treatment against the activity of an oncoprotein. Glivec is also another brand name that is a good drug threat to CML. The drug name being imatinib mesylate, we use this as the standard treatment for our patients with CML. When the patients put this drug into their stomach, it starts working almost immediately. According to the US National Library of Medicine National Institutes of Health “It binds to the kinase domain of the BCR-ABL and it inhibits the activity of the kinase domain through the stabilization of the protein in an inactive conformation.” Some potential tradeoffs when we are considering different options for a patient medical treatment plan for CML are that when these treatment plans are decided for the patient they are usually designed on how we think that the cancer is going to travel but sometimes that cancer changes paths so these treatment plans are not executed properly. When we evaluated our patients blood count we see that there is an increase in the amount of mature granulocytes and there is normal lymphocyte count. There is also an increase in the amount of basophils and eosinophils, and these usually become present and more prominent when a transition to acute leukemia takes place. When a comparison was done of our patient’s peripheral blood smear to a patient’s peripheral blood smear that doesn’t have CML we discovered that in the patient with CML there was the presence of a typical leukoerythroblastic blood picture. It also showed that the patient’s peripheral blood smear with CML consisted of immature cells that had been circulating around the bone marrow, this is similar to that of a patient’s blood smear without CML because of the immature cells circulating around and from the bone marrow. Usually when the baby of a CML patient has a genetic disorder the scientists look for extra or missing chromosomes in the karyotype.